Failure Symptoms Even When People Don’t Lose as Much Weightv
Participants were randomly assigned to receive either once-weekly semaglutide injections or an inactive placebo. People in the semaglutide group started at the lowest dose, which was then increased to a maintenance dose by week 16.
After following participants for a year, researchers found that people in the semaglutide group lost more weight and had larger reductions in symptoms related to heart failure, compared to those in the placebo group.
